Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)

 

Nintedanib dose adjustments in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): 2-year data from SENSCIS-ON

Allanore Y et al.
 

Acceder

Effects of nintedanib in subjects with limited cutaneous systemic sclerosis (lcSSc) and interstitial lung disease (ILD): data from the SENSCIS trial

Allanore Y et al.
 

Acceder

Co-creation of a telemedicine guide for patients with systemic sclerosis

Farrington S et al.


 

Acceder

 

SC-ES-09519